NCT03224013

Brief Summary

Analysis corneal and refractive stability of hyperopic laser-assisted in situ keratomileusis (LASIK) with and without concurrent prophylactic high-fluence cross-linking (CXL).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2016

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 18, 2016

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 12, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 12, 2017

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

July 15, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 21, 2017

Completed
Last Updated

July 21, 2017

Status Verified

July 1, 2017

Enrollment Period

1.3 years

First QC Date

July 15, 2017

Last Update Submit

July 18, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • assessment of changes in refractive spherical equivalent

    assessment of changes in manifest refraction by autorefractometer and then calculate spherical equivalent

    preoperative and 3 months and 6 months postoperative

Study Arms (2)

Hyperopic LASIK with crosslinking

ACTIVE COMPARATOR

group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking

Procedure: LASIK

Hyperopic LASIK only

ACTIVE COMPARATOR

group 2: hyperopic customized LASIK only

Procedure: LASIK

Interventions

LASIKPROCEDURE

LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye

Hyperopic LASIK onlyHyperopic LASIK with crosslinking

Eligibility Criteria

Age18 Years - 61 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Cases with hyperopia +1diopter to +6 diopters or hyperopic astigmatism up to 4 diopters

You may not qualify if:

  • Patients with previous intraocular or corneal surgery, active corneal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hyperopia

Interventions

Keratomileusis, Laser In Situ

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Intervention Hierarchy (Ancestors)

Corneal Surgery, LaserLaser TherapyTherapeuticsAblation TechniquesSurgical Procedures, OperativeKeratectomyRefractive Surgical ProceduresOphthalmologic Surgical Procedures

Study Officials

  • Jorge L Alio, MD

    MD, Phd, FEBO

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Interventional prospective consecutive comparative case control series of cases; 50 eyes of 25 patients with mean age 35.7 ± 12.4 (Range 18-61years) with hyperopia or hyperopic astigmatism underwent customized LASIK with concurrent prophylactic high-fluence cross-linking in right eye (group 1) and customized LASIK only in left eye (group 2). Cases with hyperopia +1D to +6D or hyperopic astigmatism up to 4D were included in the study. Patients with previous intraocular or corneal surgery, active corneal disease were excluded from the study. Main outcome measures were uncorrected visual acuity (UCVA), manifest refractive spherical equivalent (MRSE), cycloplegic refractive spherical equivalent (CRSE), keratometric measurments and spherical aberrations at 4 mm and maximum pupilnand their ecolution along 6 months postoperatively.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Ophthalmology.Faculty of Medicine

Study Record Dates

First Submitted

July 15, 2017

First Posted

July 21, 2017

Study Start

January 18, 2016

Primary Completion

May 12, 2017

Study Completion

July 12, 2017

Last Updated

July 21, 2017

Record last verified: 2017-07

Data Sharing

IPD Sharing
Will not share